New version of Enzon cancer drug secures orphan status in EU

09/30/2008 | Boston Globe (tiered subscription model), The

European regulators granted orphan-drug status for Enzon Pharmaceuticals' Oncaspar-IV, a new version of its cancer drug for acute lymphoblastic leukemia. The designation prevents other drugmakers from selling copies of Oncaspar-IV for a decade should the product receive market clearance. Oncaspar-IV destroys cancer cells by depriving them of a key amino acid.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC